Peptide therapeutics have become an essential modality in treating chronic and complex diseases, including cancer, diabetes and neurodegenerative disorders. However, peptide manufacturing presents persistent challenges, particularly peptide aggregation, which can significantly reduce product yield, bioactivity and safety.
This webinar will provide an in-depth examination of peptide aggregation during drug substance and drug product development, highlighting root causes, detection tools and effective mitigation strategies grounded in real-world case studies.
The featured speakers will begin with an overview of peptide aggregation mechanisms. They will discuss how intrinsic factors such as amino acid sequence and hydrophobicity, along with extrinsic parameters like pH, temperature, stirring and buffer composition, contribute to aggregate formation.
This webinar is ideal for professionals involved in peptide process development, formulation, analytical sciences and regulatory affairs who want to deepen their understanding of aggregation-related risks and how to manage them across the development lifecycle.
Register for this webinar to learn how to identify, monitor and control peptide aggregation. Gain practical insights, technical approaches and regulatory-aligned strategies to ensure the quality, efficacy and manufacturability of peptide therapeutics.
Details
- Date: Wednesday 18 June 2025
- Time: 10am EDT (NA) / 3pm BST (UK) / 4pm CEST (EU-Central)
- Length: 60 minutes
Speakers
- El Djouhar Rekaï, PhD, Head of Process & Analytical Development, PolyPeptide Group
- Anaïs Pujol-Collinson, PhD, Downstream Process Scientist, PolyPeptide Group
- Dinesh Parmar, Head of Regulatory Affairs Ambernath, PolyPeptide Group
For more information about the webinar and to reserve a place, please click here.